Photodynamic therapy versus combination therapy in polypoidal choroidal vasculopathy: Changes of aqueous vascular endothelial growth factor

Mee Yon Lee; Won Ki Lee; Jiwon Baek; Oh Woong Kwon; Jin Hae Lee

doi:10.1016/j.ajo.2013.04.001

Photodynamic therapy versus combination therapy in polypoidal choroidal vasculopathy: Changes of aqueous vascular endothelial growth factor

Mee Yon Lee
, Won Ki Lee
, Jiwon Baek
, Oh Woong Kwon
, Jin Hae Lee

Department of Ophthalmology

Catholic Univ. of Korea Coll. Med.
Retina Center of Nune Eye Hospital

Research output: Contribution to journal › Article › peer-review

32 Scopus citations

Abstract

Purpose: To investigate the influence of photodynamic therapy (PDT) and combination of PDT and ranibizumab on aqueous humor levels of vascular endothelial growth factor (VEGF) in polypoidal choroidal vasculopathy (PCV). Design: Prospective randomized clinical trial. Method: We included 20 eyes with treatment-naïve PCV and 20 eyes undergoing cataract surgery as controls. PCV eyes were randomized to treatment with PDT alone or to a combination of ranibizumab and PDT on the same day. During 3 months, retreatment was not performed. Aqueous humors were collected at baseline and at 1 week, 1 month, and 3 months after treatment in the PCV group and during cataract surgery in the control group. VEGF levels were measured using multiplex bead immunoassay. Results: At baseline, VEGF levels were significantly increased in PCV eyes compared with control eyes. A significant decrease in VEGF levels was found at 1 week after PDT treatment (n = 8) and at all time points after combination treatment (n = 12). With combination treatment, VEGF levels were decreased to values below the detection limit in all eyes at 1 week and 1 month and in 7 of 12 eyes at 3 months. There was no difference in the clinical profiles among the 2 treatment groups at each time point. Conclusion: Decreased levels of VEGF detected 1 week after PDT for PCV seems to reflect acute damage of vascular endothelial cells, one of the VEGF expression sites in PCV. Concomitant ranibizumab resulted in a further decrease in VEGF to negligible levels, but this result did not affect the clinical results for 3 months.

Original language	English
Pages (from-to)	343-348
Number of pages	6
Journal	American Journal of Ophthalmology
Volume	156
Issue number	2
DOIs	https://doi.org/10.1016/j.ajo.2013.04.001
State	Published - Aug 2013

Bibliographical note

Funding Information:
All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and the following were reported: Won Ki Lee: disclosures outside of the submitted work for consultancy (Novartis) and payment for lectures (Novartis, Bayer, Allergan); Oh Woong Kwon: disclosures outside of the submitted work for consultancy (Novartis, Bayer) and payment for lectures (Novartis, Bayer). This article was supported by funding from NOVARTIS KOREA , Seoul, South Korea. Contributions of authors: design and conduct of the study (W.K.L., M.Y.L.); collection (W.K.L., M.Y.L., J.B.L., O.W.K.), management (W.K.L., M.Y.L.), analysis (W.K.L., M.Y.L.), and interpretation of the data (W.K.L., M.Y.L.); and preparation (W.K.L., M.Y.L.), review, or approval of the manuscript (W.K.L., M.Y.L., J.B., J.H.L., O.W.K.).

Access to Document

10.1016/j.ajo.2013.04.001

Cite this

@article{55d7158908f249cfa0923de78580e1a2,

title = "Photodynamic therapy versus combination therapy in polypoidal choroidal vasculopathy: Changes of aqueous vascular endothelial growth factor",

abstract = "Purpose: To investigate the influence of photodynamic therapy (PDT) and combination of PDT and ranibizumab on aqueous humor levels of vascular endothelial growth factor (VEGF) in polypoidal choroidal vasculopathy (PCV). Design: Prospective randomized clinical trial. Method: We included 20 eyes with treatment-na{\"i}ve PCV and 20 eyes undergoing cataract surgery as controls. PCV eyes were randomized to treatment with PDT alone or to a combination of ranibizumab and PDT on the same day. During 3 months, retreatment was not performed. Aqueous humors were collected at baseline and at 1 week, 1 month, and 3 months after treatment in the PCV group and during cataract surgery in the control group. VEGF levels were measured using multiplex bead immunoassay. Results: At baseline, VEGF levels were significantly increased in PCV eyes compared with control eyes. A significant decrease in VEGF levels was found at 1 week after PDT treatment (n = 8) and at all time points after combination treatment (n = 12). With combination treatment, VEGF levels were decreased to values below the detection limit in all eyes at 1 week and 1 month and in 7 of 12 eyes at 3 months. There was no difference in the clinical profiles among the 2 treatment groups at each time point. Conclusion: Decreased levels of VEGF detected 1 week after PDT for PCV seems to reflect acute damage of vascular endothelial cells, one of the VEGF expression sites in PCV. Concomitant ranibizumab resulted in a further decrease in VEGF to negligible levels, but this result did not affect the clinical results for 3 months.",

author = "Lee, \{Mee Yon\} and Lee, \{Won Ki\} and Jiwon Baek and Kwon, \{Oh Woong\} and Lee, \{Jin Hae\}",

note = "Funding Information: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and the following were reported: Won Ki Lee: disclosures outside of the submitted work for consultancy (Novartis) and payment for lectures (Novartis, Bayer, Allergan); Oh Woong Kwon: disclosures outside of the submitted work for consultancy (Novartis, Bayer) and payment for lectures (Novartis, Bayer). This article was supported by funding from NOVARTIS KOREA , Seoul, South Korea. Contributions of authors: design and conduct of the study (W.K.L., M.Y.L.); collection (W.K.L., M.Y.L., J.B.L., O.W.K.), management (W.K.L., M.Y.L.), analysis (W.K.L., M.Y.L.), and interpretation of the data (W.K.L., M.Y.L.); and preparation (W.K.L., M.Y.L.), review, or approval of the manuscript (W.K.L., M.Y.L., J.B., J.H.L., O.W.K.).",

year = "2013",

month = aug,

doi = "10.1016/j.ajo.2013.04.001",

language = "English",

volume = "156",

pages = "343--348",

journal = "American Journal of Ophthalmology",

issn = "0002-9394",

publisher = "Elsevier Inc.",

number = "2",

}

TY - JOUR

T1 - Photodynamic therapy versus combination therapy in polypoidal choroidal vasculopathy

T2 - Changes of aqueous vascular endothelial growth factor

AU - Lee, Mee Yon

AU - Lee, Won Ki

AU - Baek, Jiwon

AU - Kwon, Oh Woong

AU - Lee, Jin Hae

N1 - Funding Information: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and the following were reported: Won Ki Lee: disclosures outside of the submitted work for consultancy (Novartis) and payment for lectures (Novartis, Bayer, Allergan); Oh Woong Kwon: disclosures outside of the submitted work for consultancy (Novartis, Bayer) and payment for lectures (Novartis, Bayer). This article was supported by funding from NOVARTIS KOREA , Seoul, South Korea. Contributions of authors: design and conduct of the study (W.K.L., M.Y.L.); collection (W.K.L., M.Y.L., J.B.L., O.W.K.), management (W.K.L., M.Y.L.), analysis (W.K.L., M.Y.L.), and interpretation of the data (W.K.L., M.Y.L.); and preparation (W.K.L., M.Y.L.), review, or approval of the manuscript (W.K.L., M.Y.L., J.B., J.H.L., O.W.K.).

PY - 2013/8

Y1 - 2013/8

N2 - Purpose: To investigate the influence of photodynamic therapy (PDT) and combination of PDT and ranibizumab on aqueous humor levels of vascular endothelial growth factor (VEGF) in polypoidal choroidal vasculopathy (PCV). Design: Prospective randomized clinical trial. Method: We included 20 eyes with treatment-naïve PCV and 20 eyes undergoing cataract surgery as controls. PCV eyes were randomized to treatment with PDT alone or to a combination of ranibizumab and PDT on the same day. During 3 months, retreatment was not performed. Aqueous humors were collected at baseline and at 1 week, 1 month, and 3 months after treatment in the PCV group and during cataract surgery in the control group. VEGF levels were measured using multiplex bead immunoassay. Results: At baseline, VEGF levels were significantly increased in PCV eyes compared with control eyes. A significant decrease in VEGF levels was found at 1 week after PDT treatment (n = 8) and at all time points after combination treatment (n = 12). With combination treatment, VEGF levels were decreased to values below the detection limit in all eyes at 1 week and 1 month and in 7 of 12 eyes at 3 months. There was no difference in the clinical profiles among the 2 treatment groups at each time point. Conclusion: Decreased levels of VEGF detected 1 week after PDT for PCV seems to reflect acute damage of vascular endothelial cells, one of the VEGF expression sites in PCV. Concomitant ranibizumab resulted in a further decrease in VEGF to negligible levels, but this result did not affect the clinical results for 3 months.

AB - Purpose: To investigate the influence of photodynamic therapy (PDT) and combination of PDT and ranibizumab on aqueous humor levels of vascular endothelial growth factor (VEGF) in polypoidal choroidal vasculopathy (PCV). Design: Prospective randomized clinical trial. Method: We included 20 eyes with treatment-naïve PCV and 20 eyes undergoing cataract surgery as controls. PCV eyes were randomized to treatment with PDT alone or to a combination of ranibizumab and PDT on the same day. During 3 months, retreatment was not performed. Aqueous humors were collected at baseline and at 1 week, 1 month, and 3 months after treatment in the PCV group and during cataract surgery in the control group. VEGF levels were measured using multiplex bead immunoassay. Results: At baseline, VEGF levels were significantly increased in PCV eyes compared with control eyes. A significant decrease in VEGF levels was found at 1 week after PDT treatment (n = 8) and at all time points after combination treatment (n = 12). With combination treatment, VEGF levels were decreased to values below the detection limit in all eyes at 1 week and 1 month and in 7 of 12 eyes at 3 months. There was no difference in the clinical profiles among the 2 treatment groups at each time point. Conclusion: Decreased levels of VEGF detected 1 week after PDT for PCV seems to reflect acute damage of vascular endothelial cells, one of the VEGF expression sites in PCV. Concomitant ranibizumab resulted in a further decrease in VEGF to negligible levels, but this result did not affect the clinical results for 3 months.

UR - https://www.scopus.com/pages/publications/84880573266

U2 - 10.1016/j.ajo.2013.04.001

DO - 10.1016/j.ajo.2013.04.001

M3 - Article

C2 - 23664208

AN - SCOPUS:84880573266

SN - 0002-9394

VL - 156

SP - 343

EP - 348

JO - American Journal of Ophthalmology

JF - American Journal of Ophthalmology

IS - 2

ER -

Photodynamic therapy versus combination therapy in polypoidal choroidal vasculopathy: Changes of aqueous vascular endothelial growth factor

Abstract

Bibliographical note

Access to Document

Other files and links

Fingerprint

Cite this